Get the Stockscreener App
16.91
1.62%
0.27
After Hours:
17.82
0.91
+5.38%
Pacira Biosciences Inc Stock (PCRX) Forecast
The Pacira Biosciences Inc (PCRX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $25.48, representing a +50.69% increase from the current price of $16.91. The highest analyst price target is $27.45, and the lowest is $23.51.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PCRX Price Target
Average 26.83
(+58.66% Upside)
Is Pacira Biosciences Inc (PCRX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 50.91 | Neutral |
| STOCH(9,6) | 56.79 | Neutral |
| STOCHRSI(14) | 34.27 | Neutral |
| MACD(12,26) | 0.1105 | Sell |
| ADX(14) | 14.90 | Neutral |
| William %R | -56.35 | Neutral |
| CCI(14) | -25.44 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
16.97
Sell
|
16.97
Sell
|
| MA20 |
16.99
Sell
|
16.92
Sell
|
| MA50 |
16.42
Buy
|
16.78
Buy
|
| MA100 |
16.58
Buy
|
18.05
Sell
|
| MA200 |
22.49
Sell
|
21.42
Sell
|
Buy: 3
Sell: 7
Neutral: 0
Summary: Sell
According to our latest analysis, PCRX could be considered a Moderate Sell, with 17 technical analysis indicators signaling 3 Buy signals, 8 signaling Sell signals and 6 Neutral signals. This might not be a good time to consider opening new positions on PCRX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 50.91 indicates that PCRX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 56.79 indicates that PCRX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 34.27 indicates that PCRX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 14.9 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -25.44 indicates that PCRX is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term PCRX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Pacira Biosciences Inc financial reports and earnings history, Pacira Biosciences Inc (PCRX) stock could reach $6.7129 by 2030, $6.1811 by 2040 and $12.06 by 2050. See the projected annual prices until 2050 of the Pacira Biosciences Inc stock below:
- Pacira Biosciences Inc (PCRX) is expected to reach an average price of $1.499 in 2035, with a high prediction of $5.7283 and a low estimate of $0.899. This indicates an $-91.14% rise from the last recorded price of $16.91.
- Pacira Biosciences Inc (PCRX) stock is projected to chart a bullish course in 2040, with an average price target of $3.9861, representing an $-76.43% surge from its current level. The forecast ranges from a conservative $0.4226 to a sky-high $6.1811.
- Our analysts predict Pacira Biosciences Inc (PCRX) to jump -82.62% by 2045, soaring from $6.6193 to an average price of $2.9393, potentially reaching $3.8951. While $6.6193 is the low estimate, the potential upside is significant.
- Pacira Biosciences Inc (PCRX) stock is expected to climb by 2050, reaching an average of $6.3302, a $-62.57% jump from its current level. However, a wide range of estimates exists, with high and low targets of $12.06 and $9.9902, respectively, highlighting the market's uncertainty.
Pacira Biosciences Inc Stock (PCRX) Year by Year Forecast
Pacira Biosciences Inc Stock (PCRX) Price Forecast for 2025
Pacira Biosciences Inc Stock (PCRX) is expected to reach an average price of $26.83 in 2025, with a high prediction of $45.70 and a low estimate of $7.9623. This indicates an +58.66% rise from the last recorded price of $16.91.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $24.73 | $23.51 | $27.45 | +46.27% |
| February, 2025 | $23.32 | $22.16 | $25.37 | +37.91% |
| March, 2025 | $22.95 | $21.33 | $31.70 | +35.70% |
| April, 2025 | $13.92 | $7.9623 | $24.28 | -17.66% |
| May, 2025 | $19.02 | $11.07 | $20.01 | +12.47% |
| June, 2025 | $22.25 | $18.74 | $26.62 | +31.55% |
| July, 2025 | $26.03 | $21.90 | $30.24 | +53.95% |
| August, 2025 | $38.87 | $23.64 | $39.45 | +129.85% |
| September, 2025 | $39.54 | $32.64 | $41.02 | +133.85% |
| October, 2025 | $41.86 | $39.99 | $45.70 | +147.55% |
| November, 2025 | $41.60 | $37.78 | $43.80 | +145.99% |
| December, 2025 | $33.93 | $29.86 | $42.86 | +100.68% |
Pacira Biosciences Inc Stock (PCRX) Price Forecast for 2026
The predicted value for Pacira Biosciences Inc (PCRX) in 2026 is set at an average of $46.76. Estimates vary from a peak of $62.20 to a trough of $31.32, indicating an +176.51% surge from the present price of $16.91.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $45.56 | $31.32 | $49.84 | +169.43% |
| February, 2026 | $41.63 | $37.72 | $46.04 | +146.16% |
| March, 2026 | $55.69 | $38.62 | $59.90 | +229.34% |
| April, 2026 | $58.04 | $48.13 | $62.12 | +243.22% |
| May, 2026 | $52.35 | $47.04 | $62.20 | +209.61% |
| June, 2026 | $50.67 | $48.92 | $55.56 | +199.65% |
| July, 2026 | $44.79 | $41.53 | $53.01 | +164.86% |
| August, 2026 | $43.22 | $41.47 | $49.63 | +155.61% |
| September, 2026 | $39.78 | $38.13 | $46.82 | +135.25% |
| October, 2026 | $43.93 | $37.45 | $45.60 | +159.77% |
| November, 2026 | $42.40 | $37.38 | $44.02 | +150.75% |
| December, 2026 | $39.30 | $36.96 | $43.58 | +132.40% |
Pacira Biosciences Inc Stock (PCRX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Pacira Biosciences Inc (PCRX) is $47.42, with a high forecast of $66.44 and a low forecast of $28.41. This indicates an +180.45% increase from the last price of $16.91.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $36.02 | $28.41 | $40.77 | +112.98% |
| February, 2027 | $39.23 | $34.43 | $43.41 | +132.00% |
| March, 2027 | $41.42 | $34.16 | $43.17 | +144.93% |
| April, 2027 | $47.88 | $40.35 | $48.07 | +183.17% |
| May, 2027 | $48.29 | $43.35 | $50.48 | +185.57% |
| June, 2027 | $56.42 | $44.44 | $56.45 | +233.63% |
| July, 2027 | $60.53 | $53.26 | $61.63 | +257.97% |
| August, 2027 | $58.86 | $55.41 | $66.44 | +248.07% |
| September, 2027 | $48.94 | $43.17 | $61.31 | +189.39% |
| October, 2027 | $38.34 | $34.76 | $50.27 | +126.74% |
| November, 2027 | $41.72 | $36.65 | $44.08 | +146.70% |
| December, 2027 | $42.46 | $35.45 | $44.10 | +151.12% |
Pacira Biosciences Inc Stock (PCRX) Price Forecast for 2028
In 2028, Pacira Biosciences Inc (PCRX) is projected to reach an average price of $32.39, with a high projection of $43.68 and a low estimate of $21.10. This indicates an +91.54% rise from the last price of $16.91.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $36.73 | $36.26 | $43.68 | +117.21% |
| February, 2028 | $38.35 | $35.49 | $42.89 | +126.77% |
| March, 2028 | $37.07 | $35.65 | $43.29 | +119.24% |
| April, 2028 | $35.13 | $31.44 | $38.70 | +107.74% |
| May, 2028 | $25.27 | $23.29 | $35.29 | +49.42% |
| June, 2028 | $21.25 | $21.18 | $25.39 | +25.68% |
| July, 2028 | $25.80 | $21.10 | $28.97 | +52.56% |
| August, 2028 | $26.06 | $25.11 | $30.47 | +54.08% |
| September, 2028 | $28.06 | $23.70 | $28.16 | +65.94% |
| October, 2028 | $29.15 | $27.25 | $34.86 | +72.36% |
| November, 2028 | $25.50 | $23.04 | $30.10 | +50.82% |
| December, 2028 | $26.61 | $21.95 | $28.16 | +57.36% |
Pacira Biosciences Inc Stock (PCRX) Price Forecast for 2029
The 2029 price forecast for Pacira Biosciences Inc Stock (PCRX) is $15.32 on average, with a high prediction of $27.02 and a low estimate of $3.62. This represents an -9.40% decrease from the previous price of $16.91.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $23.05 | $22.12 | $27.02 | +36.29% |
| February, 2029 | $23.98 | $20.81 | $26.89 | +41.83% |
| March, 2029 | $20.59 | $19.62 | $24.41 | +21.75% |
| April, 2029 | $16.21 | $15.38 | $22.26 | -4.11% |
| May, 2029 | $15.71 | $13.73 | $18.50 | -7.09% |
| June, 2029 | $15.17 | $13.26 | $16.38 | -10.31% |
| July, 2029 | $21.22 | $14.52 | $22.00 | +25.51% |
| August, 2029 | $20.23 | $18.55 | $23.50 | +19.64% |
| September, 2029 | $17.81 | $15.07 | $20.32 | +5.30% |
| October, 2029 | $16.59 | $15.75 | $19.35 | -1.87% |
| November, 2029 | $14.30 | $13.81 | $17.53 | -15.44% |
| December, 2029 | $5.88 | $3.62 | $15.26 | -65.23% |
Pacira Biosciences Inc Stock (PCRX) Price Forecast for 2030
Pacira Biosciences Inc Stock (PCRX) is expected to reach an average price of $6.0271 in 2030, with a high forecast of $12.04 and a low forecast of $0.0116. This signifies an -64.36% decrease from the last price of $16.91.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.9595 | $0.0116 | $6.7129 | -88.41% |
| February, 2030 | $0.344 | $0.0781 | $3.8002 | -97.97% |
| March, 2030 | $2.4376 | $0.4747 | $3.8947 | -85.58% |
| April, 2030 | $3.8459 | $0.4895 | $4.2405 | -77.26% |
| May, 2030 | $2.5614 | $3.0064 | $3.538 | -84.85% |
| June, 2030 | $0.8148 | $2.4748 | $1.8535 | -95.18% |
| July, 2030 | $4.0196 | $0.339 | $4.8638 | -76.23% |
| August, 2030 | $5.6012 | $4.2725 | $7.4812 | -66.88% |
| September, 2030 | $2.6128 | $2.3128 | $6.5241 | -84.55% |
| October, 2030 | $10.64 | $2.3756 | $11.48 | -37.10% |
| November, 2030 | $4.8412 | $0.9741 | $12.04 | -71.37% |
| December, 2030 | $8.2347 | $7.1876 | $5.7554 | -51.30% |
1.11%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):